EUVIMEDEUVIMED entdecken
Open Access

Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Robert W Holloway, Alberto A Mendivil, James E Kendrick, Lisa N Abaid, John V Brown, Jane LeBlanc, Nathalie D McKenzie, Kristina M Mori, Sarfraz Ahmad

JAMA Oncology · 01.07.2023 · 9 (7) · 903

DOI: 10.1001/jamaoncol.2023.1007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Oncology, erschienen am 01.07.2023. Verfasst von Robert W Holloway und 8 weiteren Autor:innen. Beteiligte Einrichtung: AdventHealth Cancer Institute, Orlando, Florida. Hauptthemen laut MEDLINE: Smallpox, Vaccinia, Ovarian Neoplasms. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Patients with platinum-resistant or platinum-refractory ovarian cancer (PRROC) have limited therapeutic options, representing a considerable unmet medical need.

Objective

To assess antitumor activity and safety of intraperitoneal (IP) olvimulogene nanivacirepvec (Olvi-Vec) virotherapy and platinum-based chemotherapy with or without bevacizumab in patients with PRROC. Design, Setting, and Participants This open-label, nonrandomized multisite phase 2 VIRO-15 clinical trial enrolled patients with PRROC with disease progression following their last prior line of therapy from September 2016 to September 2019. Data cutoff was on March 31, 2022, and data were analyzed between April 2022 and September 2022.

Interventions

Olvi-Vec was administered via a temporary IP dialysis catheter as 2 consecutive daily doses (3 × 10 9 pfu/d) followed by platinum-doublet chemotherapy with or without bevacizumab. Main Outcomes and Measures Primary outcomes were objective response rate (ORR) via Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) and cancer antigen 125 (CA-125) assay, and progression-free survival (PFS). Secondary outcomes included duration of response (DOR), disease control rate (DCR), safety, and overall survival (OS).

Results

Twenty-seven heavily pretreated patients with platinum-resistant (n = 14) or platinum-refractory (n = 13) ovarian cancer were enrolled. The median (range) age was 62 (35-78) years. The median (range) prior lines of therapy were 4 (2-9). All patients completed both Olvi-Vec infusions and chemotherapy. Median follow-up duration was 47.0 months (95% CI, 35.9 months to NA). Overall, ORR by RECIST 1.1 was 54% (95% CI, 33%-74%), with a DOR of 7.6 months (95% CI, 3.7-9.6 months). The DCR was 88% (21/24). The ORR by CA-125 was 85% (95% CI, 65%-96%). Median PFS by RECIST 1.1 was 11.0 months (95% CI, 6.7-13.0 months), and the PFS 6-month rate was 77%. Median PFS was 10.0 months (95% CI, 6.4-NA months) in the platinum-resistant group and 11.4 months (95% CI, 4.3-13.2 months) in the platinum-refractory group. The median OS was 15.7 months (95% CI, 12.3-23.8 months) in all patients, with a median OS of 18.5 months (95% CI, 11.3-23.8 months) in the platinum-resistant group and 14.7 months (95% CI, 10.8-33.6 months) in the platinum-refractory group. Most frequent treatment-related adverse events (TRAEs) (any grade, grade 3) were pyrexia (63.0%, 3.7%, respectively) and abdominal pain (51.9%, 7.4%, respectively). There were no grade 4 TRAEs, and no treatment-related discontinuations or deaths. Conclusions and Relevance In this phase 2 nonrandomized clinical trial, Olvi-Vec followed by platinum-based chemotherapy with or without bevacizumab as immunochemotherapy demonstrated promising ORR and PFS with a manageable safety profile in patients with PRROC. These hypothesis-generating results warrant further evaluation in a confirmatory phase 3 trial. Trial Registration ClinicalTrials.gov Identifier: NCT02759588

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SmallpoxVacciniaOvarian NeoplasmsHumansFemaleMiddle AgedAgedBevacizumabPlatinumAntineoplastic Combined Chemotherapy Protocols

Substanzen

BevacizumabPlatinum

Autor:innen und Institutionen

  • AdventHealth Cancer Institute, Orlando, Florida.
  • Gynecologic Oncology Associates, Newport Beach, California.
  • Now with Gynecologic Oncology and Complex Pelvic Surgery Program, Hoag Gynecologic Oncology, Newport Beach, California.
  • now with Kaiser Permanente, Santa Clara, California.

Zitieren

APA

Holloway, R. W., Mendivil, A. A., Kendrick, J. E., Abaid, L. N., Brown, J. V., LeBlanc, J., McKenzie, N. D., Mori, K. M., & Ahmad, S. (2023). Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer. JAMA Oncology, 9(7), 903. https://doi.org/10.1001/jamaoncol.2023.1007

Vancouver

Holloway RW, Mendivil AA, Kendrick JE, Abaid LN, Brown JV, LeBlanc J, et al. Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer. JAMA Oncology. 2023;9(7):903. doi:10.1001/jamaoncol.2023.1007

BibTeX
@article{Holloway2023,
  author = {Holloway, Robert W and Mendivil, Alberto A and Kendrick, James E and Abaid, Lisa N and Brown, John V and LeBlanc, Jane and McKenzie, Nathalie D and Mori, Kristina M and Ahmad, Sarfraz},
  title = {Clinical Activity of Olvimulogene Nanivacirepvec–Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer},
  journal = {JAMA Oncology},
  year = {2023},
  volume = {9},
  number = {7},
  pages = {903},
  doi = {10.1001/jamaoncol.2023.1007}
}
Kostenlos starten →